Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Assessing the Impact of Cyclosporin A on Lentiviral Transduction and Preservation of Human Hematopoietic Stem Cells in Clinically Relevant Ex Vivo Gene Therapy Settings.

Petrillo C, Calabria A, Piras F, Capotondo A, Spinozzi G, Cuccovillo I, Benedicenti F, Naldini L, Montini E, Biffi A, Gentner B, Kajaste-Rudnitski A.

Hum Gene Ther. 2019 Sep;30(9):1133-1146. doi: 10.1089/hum.2019.016. Epub 2019 May 24.

2.

Cyclosporine H Overcomes Innate Immune Restrictions to Improve Lentiviral Transduction and Gene Editing In Human Hematopoietic Stem Cells.

Petrillo C, Thorne LG, Unali G, Schiroli G, Giordano AMS, Piras F, Cuccovillo I, Petit SJ, Ahsan F, Noursadeghi M, Clare S, Genovese P, Gentner B, Naldini L, Towers GJ, Kajaste-Rudnitski A.

Cell Stem Cell. 2018 Dec 6;23(6):820-832.e9. doi: 10.1016/j.stem.2018.10.008. Epub 2018 Nov 8.

3.

Lentiviral vectors escape innate sensing but trigger p53 in human hematopoietic stem and progenitor cells.

Piras F, Riba M, Petrillo C, Lazarevic D, Cuccovillo I, Bartolaccini S, Stupka E, Gentner B, Cittaro D, Naldini L, Kajaste-Rudnitski A.

EMBO Mol Med. 2017 Sep;9(9):1198-1211. doi: 10.15252/emmm.201707922.

4.

Efficient Ex Vivo Engineering and Expansion of Highly Purified Human Hematopoietic Stem and Progenitor Cell Populations for Gene Therapy.

Zonari E, Desantis G, Petrillo C, Boccalatte FE, Lidonnici MR, Kajaste-Rudnitski A, Aiuti A, Ferrari G, Naldini L, Gentner B.

Stem Cell Reports. 2017 Apr 11;8(4):977-990. doi: 10.1016/j.stemcr.2017.02.010. Epub 2017 Mar 16.

5.

HIV-1 transcriptional silencing caused by TRIM22 inhibition of Sp1 binding to the viral promoter.

Turrini F, Marelli S, Kajaste-Rudnitski A, Lusic M, Van Lint C, Das AT, Harwig A, Berkhout B, Vicenzi E.

Retrovirology. 2015 Dec 18;12:104. doi: 10.1186/s12977-015-0230-0.

6.

Cellular innate immunity and restriction of viral infection: implications for lentiviral gene therapy in human hematopoietic cells.

Kajaste-Rudnitski A, Naldini L.

Hum Gene Ther. 2015 Apr;26(4):201-9. doi: 10.1089/hum.2015.036. Epub 2015 Apr 13. Review.

PMID:
25808164
7.

Cyclosporin a and rapamycin relieve distinct lentiviral restriction blocks in hematopoietic stem and progenitor cells.

Petrillo C, Cesana D, Piras F, Bartolaccini S, Naldini L, Montini E, Kajaste-Rudnitski A.

Mol Ther. 2015 Feb;23(2):352-62. doi: 10.1038/mt.2014.193. Epub 2014 Oct 1.

8.

Dual-regulated lentiviral vector for gene therapy of X-linked chronic granulomatosis.

Chiriaco M, Farinelli G, Capo V, Zonari E, Scaramuzza S, Di Matteo G, Sergi LS, Migliavacca M, Hernandez RJ, Bombelli F, Giorda E, Kajaste-Rudnitski A, Trono D, Grez M, Rossi P, Finocchi A, Naldini L, Gentner B, Aiuti A.

Mol Ther. 2014 Aug;22(8):1472-1483. doi: 10.1038/mt.2014.87. Epub 2014 May 29.

9.

Genetic engineering of hematopoiesis for targeted IFN-α delivery inhibits breast cancer progression.

Escobar G, Moi D, Ranghetti A, Ozkal-Baydin P, Squadrito ML, Kajaste-Rudnitski A, Bondanza A, Gentner B, De Palma M, Mazzieri R, Naldini L.

Sci Transl Med. 2014 Jan 1;6(217):217ra3. doi: 10.1126/scitranslmed.3006353.

10.

Identification of TRIM22 single nucleotide polymorphisms associated with loss of inhibition of HIV-1 transcription and advanced HIV-1 disease.

Ghezzi S, Galli L, Kajaste-Rudnitski A, Turrini F, Marelli S, Toniolo D, Casoli C, Riva A, Poli G, Castagna A, Vicenzi E.

AIDS. 2013 Sep 24;27(15):2335-44. doi: 10.1097/01.aids.0000432474.76873.5f.

PMID:
23921607
11.

Lipid-based nanoparticles as nonviral gene delivery vectors.

Pezzoli D, Kajaste-Rudnitski A, Chiesa R, Candiani G.

Methods Mol Biol. 2013;1025:269-79. doi: 10.1007/978-1-62703-462-3_21.

PMID:
23918345
12.

M1 polarization of human monocyte-derived macrophages restricts pre and postintegration steps of HIV-1 replication.

Cassetta L, Kajaste-Rudnitski A, Coradin T, Saba E, Della Chiara G, Barbagallo M, Graziano F, Alfano M, Cassol E, Vicenzi E, Poli G.

AIDS. 2013 Jul 31;27(12):1847-56.

PMID:
23612004
13.

TRIM22 inhibits influenza A virus infection by targeting the viral nucleoprotein for degradation.

Di Pietro A, Kajaste-Rudnitski A, Oteiza A, Nicora L, Towers GJ, Mechti N, Vicenzi E.

J Virol. 2013 Apr;87(8):4523-33. doi: 10.1128/JVI.02548-12. Epub 2013 Feb 13.

14.

Assessment of efficacy and safety of pandemic A/H1N1/2009 influenza vaccine in a group of health care workers.

Mascagni P, Vicenzi E, Kajaste-Rudnitski A, Pellicciotta G, Monti A, Cervi C, Vitalucci R, Toffoletto F.

Med Lav. 2012 May-Jun;103(3):220-9.

PMID:
22838300
15.

HIV-1 envelope-dependent restriction of CXCR4-using viruses in child but not adult untransformed CD4+ T-lymphocyte lines.

Mariani SA, Brigida I, Kajaste-Rudnitski A, Ghezzi S, Rocchi A, Plebani A, Vicenzi E, Aiuti A, Poli G.

Blood. 2012 Mar 1;119(9):2013-23. doi: 10.1182/blood-2010-12-325308. Epub 2012 Jan 10.

PMID:
22234680
16.

TRIM22 inhibits HIV-1 transcription independently of its E3 ubiquitin ligase activity, Tat, and NF-kappaB-responsive long terminal repeat elements.

Kajaste-Rudnitski A, Marelli SS, Pultrone C, Pertel T, Uchil PD, Mechti N, Mothes W, Poli G, Luban J, Vicenzi E.

J Virol. 2011 May;85(10):5183-96. doi: 10.1128/JVI.02302-10. Epub 2011 Feb 23.

17.

Induction of protective antibody response by MF59-adjuvanted 2009 pandemic A/H1N1v influenza vaccine in HIV-1-infected individuals.

Kajaste-Rudnitski A, Galli L, Nozza S, Tambussi G, Di Pietro A, Pellicciotta G, Monti A, Mascagni P, Moro M, Vicenzi E.

AIDS. 2011 Jan 14;25(2):177-83. doi: 10.1097/QAD.0b013e328341afa8.

PMID:
21150561
18.

Viral determinants in the NS3 helicase and 2K peptide that promote West Nile virus resistance to antiviral action of 2',5'-oligoadenylate synthetase 1b.

Mertens E, Kajaste-Rudnitski A, Torres S, Funk A, Frenkiel MP, Iteman I, Khromykh AA, Desprès P.

Virology. 2010 Mar 30;399(1):176-185. doi: 10.1016/j.virol.2009.12.036. Epub 2010 Jan 25.

19.

Restriction factors of retroviral replication: the example of Tripartite Motif (TRIM) protein 5 alpha and 22.

Kajaste-Rudnitski A, Pultrone C, Marzetta F, Ghezzi S, Coradin T, Vicenzi E.

Amino Acids. 2010 Jun;39(1):1-9. doi: 10.1007/s00726-009-0393-x. Epub 2009 Nov 27. Review.

PMID:
19943174
20.

Pandemic vaccine preparedness--have we left something behind?

Capua I, Kajaste-Rudnitski A, Bertoli E, Vicenzi E.

PLoS Pathog. 2009 Jun;5(6):e1000482. doi: 10.1371/journal.ppat.1000482. Epub 2009 Jun 26. No abstract available.

21.

Inhibition of herpes simplex virus types 1 and 2 in vitro infection by sulfated derivatives of Escherichia coli K5 polysaccharide.

Pinna D, Oreste P, Coradin T, Kajaste-Rudnitski A, Ghezzi S, Zoppetti G, Rotola A, Argnani R, Poli G, Manservigi R, Vicenzi E.

Antimicrob Agents Chemother. 2008 Sep;52(9):3078-84. doi: 10.1128/AAC.00359-08. Epub 2008 Jun 23.

22.

A dimerizable cationic lipid with potential for gene delivery.

Candiani G, Pezzoli D, Cabras M, Ristori S, Pellegrini C, Kajaste-Rudnitski A, Vicenzi E, Sala C, Zanda M.

J Gene Med. 2008 Jun;10(6):637-45. doi: 10.1002/jgm.1186.

PMID:
18338839
23.

The 2',5'-oligoadenylate synthetase 1b is a potent inhibitor of West Nile virus replication inside infected cells.

Kajaste-Rudnitski A, Mashimo T, Frenkiel MP, Guénet JL, Lucas M, Desprès P.

J Biol Chem. 2006 Feb 24;281(8):4624-37. Epub 2005 Dec 21.

24.

A variant in the CD209 promoter is associated with severity of dengue disease.

Sakuntabhai A, Turbpaiboon C, Casadémont I, Chuansumrit A, Lowhnoo T, Kajaste-Rudnitski A, Kalayanarooj SM, Tangnararatchakit K, Tangthawornchaikul N, Vasanawathana S, Chaiyaratana W, Yenchitsomanus PT, Suriyaphol P, Avirutnan P, Chokephaibulkit K, Matsuda F, Yoksan S, Jacob Y, Lathrop GM, Malasit P, Desprès P, Julier C.

Nat Genet. 2005 May;37(5):507-13. Epub 2005 Apr 17.

PMID:
15838506

Supplemental Content

Loading ...
Support Center